Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cataract - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cataract - Pipeline Review, H2 2014', provides an overview of the Cataract's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cataract - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cataract - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cataract Overview 6 Therapeutics Development 7 Pipeline Products for Cataract - Overview 7 Pipeline Products for Cataract - Comparative Analysis 8 Cataract - Therapeutics under Development by Companies 9 Cataract - Therapeutics under Investigation by Universities/Institutes 10 Cataract - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Cataract - Products under Development by Companies 13 Cataract - Products under Investigation by Universities/Institutes 14 Cataract - Companies Involved in Therapeutics Development 15 CalAsia Pharmaceuticals, Inc. 15 EyeGate Pharmaceuticals, Inc. 16 InSite Vision Incorporated 17 Laboratorios Sophia S.A. de C.V. 18 Laila Pharmaceuticals Pvt. Ltd. 19 Cataract - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 29 (bromfenac + dexamethasone) - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 dexamethasone acetate - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Drug For Cataract - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Drugs for Cataract - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 LP-01309 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PRO-155 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cataract - Recent Pipeline Updates 41 Cataract - Dormant Projects 43 Cataract - Discontinued Products 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 46 Disclaimer 46
List of Tables Number of Products under Development for Cataract, H2 2014 7 Number of Products under Development for Cataract - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Cataract - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 15 Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2014 16 Cataract - Pipeline by InSite Vision Incorporated, H2 2014 17 Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2014 18 Cataract - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Assessment by Combination Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 28 Cataract Therapeutics - Recent Pipeline Updates, H2 2014 41 Cataract - Dormant Projects, H2 2014 43 Cataract - Discontinued Products, H2 2014 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.